Michael Dickinson is Lead of the Aggressive Lymphoma Disease Group at Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He is experienced as a principal investigator in phase I/II clincial trials of new anticancer drugs across a breadth of haematological malignancies and harnessing a range of biological mechanisms. His investigator-initiated studies have focussed on the role of epigenetic modifiers in haematological malignancies and of eltrombopag as a supportive care agent in myeloid malignancy. Michael’s current clinical research includes first in human to phase II/III trials predominantly in aggressive lymphomas. (DLBCL, T-Cell Lymphoma, Hodgkin Lymphoma). The trial team he works with is globally competitive at rapidly and safely delivering novel immunotherapeutic and epigenetic trials in lymphoma, including CAR-T trials. The portfolio at Peter Mac/RMH is the best in the country and continues to build. Michael is focussed turning these treatments into an every day option for Australian patients. He prides himself on providing thorough and personal care to his patients through their cancer journey.
